Allogene Therapeutics (ALLO) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ALLO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript…

Allogene Therapeutics, Inc. ( ALLO ) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases November 9, 2026 9:00 AM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affai…

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

Allogene Therapeutics, Inc. ( ALLO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President…

Allogene Therapeutics NASDAQ: ALLO expects to complete enrollment in its ALPHA3 lymphoma trial by the end of 2027, as increased screening and activity in Asia-Pacific help support recruitment, executives said on the comp…

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

Bank of America Corp DE bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission.…

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?…

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during a recent quarter, according to its most recent disclosure with the Securities and Exchange …

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for c…

Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in a recent quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,9…

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during a recent quarter, according to the company in its most recent filing with the Secur…

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations su…

Bank of America Corp DE lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 111.9% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchan…
Kept in their own lane. A press release is the company talking, not reporting.

